Weaver Lindell K, Wilson Steffanie H, Lindblad Anne S, Churchill Susan, Deru Kayla, Price Robert C, Williams Chris S, Orrison William W, Walker James M, Meehan Anna, Mirow Susan
Division of Hyperbaric Medicine Intermountain Medical Center, Murray, Utah, and Intermountain LDS Hospital, Salt Lake City, Utah.
University of Utah School of Medicine, Salt Lake City, Utah.
Undersea Hyperb Med. 2018 Mar-Apr;45(2):129-156.
In prior military randomized trials, participants with persistent symptoms after mild traumatic brain injury (TBI) reported improvement regardless of receiving hyperbaric oxygen (HBO₂) or sham intervention. This study's objectives were to identify outcomes for future efficacy trials and describe changes by intervention.
This Phase II, randomized, double-blind, sham-controlled trial enrolled military personnel with mild TBI and persistent post-concussive symptoms. Participants were randomized to receive 40 HBO₂ (1.5 atmospheres absolute (ATA), ⟩99% oxygen, 60 minutes) or sham chamber sessions (1.2 ATA, room air, 60 minutes) over 12 weeks. Participants and evaluators were blinded to allocation. Outcomes assessed at baseline, 13 weeks and six months included symptoms, quality of life, neuropsychological, neurological, electroencephalography, sleep, auditory, vestibular, autonomic, visual, neuroimaging, and laboratory testing. Participants completed 12-month questionnaires. Intention-to-treat results are reported.
From 9/11/2012 to 5/19/2014, 71 randomized participants received HBO₂ (n=36) or sham (n=35). At baseline, 35 participants (49%) met post-traumatic stress disorder (PTSD) criteria. By the Neurobehavioral Symptom Inventory, the HBO₂ group had improved 13-week scores (mean change -3.6 points, P=0.03) compared to sham (+3.9 points). In participants with PTSD, change with HBO₂ was more pronounced (-8.6 vs. +4.8 points with sham, P=0.02). PTSD symptoms also improved in the HBO₂ group, and more so in the subgroup with PTSD. Improvements regressed at six and 12 months. Hyperbaric oxygen improved some cognitive processing speed and sleep measures. Participants with PTSD receiving HBO₂ had improved functional balance and reduced vestibular complaints at 13 weeks.
By 13 weeks, HBO₂ improved post-concussive and PTSD symptoms, cognitive processing speed, sleep quality, and balance function, most dramatically in those with PTSD. Changes did not persist beyond six months. Several outcomes appeared sensitive to change; additional studies are warranted.
在先前的军事随机试验中,轻度创伤性脑损伤(TBI)后仍有持续症状的参与者无论接受高压氧(HBO₂)治疗还是假干预,均报告症状有所改善。本研究的目的是确定未来疗效试验的结果,并描述不同干预措施带来的变化。
这项II期随机双盲假对照试验纳入了患有轻度TBI和持续性脑震荡后症状的军事人员。参与者被随机分配接受40次HBO₂治疗(绝对压力1.5个大气压(ATA),氧气含量>99%,60分钟)或假舱治疗(1.2 ATA,室内空气,60分钟),为期12周。参与者和评估者均对分配情况不知情。在基线、13周和6个月时评估的结果包括症状、生活质量、神经心理学、神经学、脑电图、睡眠、听觉、前庭、自主神经、视觉、神经影像学和实验室检查。参与者完成了12个月的问卷调查。报告意向性治疗结果。
从2012年9月11日至2014年5月19日,71名随机分组的参与者接受了HBO₂治疗(n = 36)或假治疗(n = 35)。在基线时,35名参与者(49%)符合创伤后应激障碍(PTSD)标准。根据神经行为症状量表,与假治疗组(平均变化+3.9分)相比,HBO₂组在13周时得分有所改善(平均变化-3.6分,P = 0.03)。在患有PTSD的参与者中,HBO₂治疗带来的变化更为明显(-8.6分 vs. 假治疗组的+4.8分,P = 0.02)。HBO₂组的PTSD症状也有所改善,在患有PTSD的亚组中改善更为明显。在6个月和12个月时,改善情况有所消退。高压氧改善了一些认知处理速度和睡眠指标。接受HBO₂治疗的患有PTSD的参与者在13周时功能平衡得到改善,前庭不适减少。
到13周时,HBO₂改善了脑震荡后和PTSD症状、认知处理速度、睡眠质量和平衡功能,在患有PTSD的参与者中最为显著。这些变化在6个月后没有持续。一些结果似乎对变化敏感;有必要进行更多研究。